Welcome to our dedicated page for Fresenius Med Cr news (Ticker: FMS), a resource for investors and traders seeking the latest updates and insights on Fresenius Med Cr stock.
Fresenius Medical Care AG reports developments in kidney care, dialysis services, and dialysis products for individuals with renal disease. Company news commonly covers Care Delivery clinic operations, Care Enablement products such as dialysis machines, dialyzers, and the 5008X CAREsystem, and Value-Based Care activity, along with organic revenue, operating income, margins, leverage, and share buyback updates.
Other recurring items include portfolio optimization, research in hemodiafiltration, artificial intelligence and digital tools for nephrology, and governance changes affecting the Management Board and Supervisory Board. Updates also describe the company's Frankfurt and New York listings and shareholder matters tied to its ordinary shares and ADRs.
Fresenius Medical Care (NYSE:FMS) announced publication in the Journal of the American Society of Nephrology of a large multinational real-world evidence study comparing hemodiafiltration (HDF) with conventional high-flux hemodialysis.
In nearly 20,000 patients across eight European countries, HDF was associated with a 28% lower relative risk of all-cause mortality. High-volume HDF (HVHDF), defined by sustained convection volumes above 23 liters per session, was associated with a 33% lower relative risk of death. The analysis used a target trial emulation design with advanced statistical methods and aligns with prior evidence, including the EU-funded CONVINCE trial, reinforcing HVHDF’s role in modern dialysis care.
Fresenius Medical Care (FMS) reported Q2 2026 revenue of EUR 4,861 million, up 1% year-on-year (+5% organic) with growth in all operating segments. Operating income rose 10% to EUR 466 million, while operating income excluding special items increased 20% to EUR 569 million, expanding the margin2 to 11.7%.
Net income declined 3% to EUR 218 million, but net income excluding special items grew 13% to EUR 303 million. Basic EPS increased 6% to EUR 0.81, and EPS excluding special items rose 24% to EUR 1.13, supported by share buybacks. Operating cash flow grew 11% to EUR 860 million; free cash flow was stable at EUR 625 million.
The FME25+ program delivered EUR 67 million additional sustainable savings in Q2, with around 100 U.S. clinics exited and related EUR 42 million special costs. The company cancelled 24.8 million shares (8.5% of capital) and began a second buyback of about EUR 1 billion. Fresenius Medical Care reaffirmed its 2026 outlook for broadly flat revenue and operating income2 within a mid-single digit range at constant currency, excluding special items.
Fresenius Medical Care (NYSE:FMS) announced that its Supervisory Board has appointed Cassie McLean (48) to the Management Board as Chief Executive Officer of the Care Delivery operating segment, effective 1 August 2026. She succeeds Craig Cordola (54), the prior CEO of Care Delivery.
McLean, who joined the company in August 2025 as President, Fresenius Kidney Care, will assume direct accountability for the global clinic business, including Fresenius Kidney Care in the U.S. and Care Delivery International. She previously served as CEO of Monte Nido and spent nearly 16 years at DaVita Kidney Care.
Fresenius Medical Care (NYSE:FMS) announced BEACON-US, a U.S. research initiative evaluating clinical outcomes and patient experience with high-volume hemodiafiltration (HVHDF) in routine dialysis practice. The program supports the company’s nationwide roll-out of online-HDF and its FME Reignite growth and innovation strategy.
According to Fresenius Medical Care, early U.S. observations show 40% fewer muscle cramps and more than 70% of treatments using AutoSub plus technology reaching the HVHDF target of at least 23 liters convective volume per session. International evidence, including the EU-funded CONVINCE trial, has associated HVHDF with fewer hospitalizations and a 23% lower risk of death versus conventional high-flux hemodialysis.
Fresenius Medical Care (NYSE:FMS) introduced TherapyWise, a cloud-based analytics capability integrated into NxView 4.0, the FDA 510(k)-cleared software platform used with the NxStage System One for kidney replacement therapy in U.S. acute and critical care settings.
TherapyWise aggregates retrospective program-level data from ICU kidney replacement therapy, summarizing metrics such as average delivered versus set dose, treatment time per cartridge, and alarm frequency trends. It is designed for oversight and quality improvement, not real-time patient-specific decision-making, which remains the responsibility of attending clinicians.
Fresenius Medical Care (NYSE:FMS) launched kinexus, a unified digital platform for home dialysis programs worldwide. The modular system connects remote therapy monitoring, prescription management, and supply ordering for peritoneal dialysis and home hemodialysis in one interface.
Built on the Huma Cloud Platform, kinexus supports global rollout aligned with local regulatory and operational requirements.
Fresenius Medical Care (NYSE:FMS) launched the first tranche of a new share buyback program with a total planned volume of around EUR 1 billion. The initial tranche of up to EUR 600 million starts May 28, 2026 and is expected to run until December 15, 2026, under authorization granted at the May 21, 2026 AGM.
Fresenius Medical Care (NYSE:FMS) will showcase new renal research and digital innovation at the ERA Congress 2026 in Glasgow and virtually, June 3‑6.
Highlights include evidence-based hemodiafiltration studies, AI-driven tools for dialysis care, patient-centered outcomes research, and a preview of the kinexus home dialysis digital platform.
Fresenius Medical Care (NYSE:FMS) plans a new share buyback program with a total volume of around EUR 1 billion, to be executed in tranches over 12 months from launch.
The program, authorized by the May 21, 2026 AGM, is expected to start soon and follows completion of a prior EUR 1 billion buyback on April 30, 2026. According to the company, the initiative is part of its capital allocation framework, complements dividends, and is supported by strong operating cash-flow generation.
Fresenius Medical Care (NYSE:FMS) reported a milestone year with higher profitability and strong shareholder returns. Organic revenue grew 8% at constant currency and the adjusted group operating margin reached 11.3%, up from 7.9% three years earlier.
Net leverage fell to 2.5x from 3.4x in 2022. Shareholders approved a higher dividend of EUR 1.49 per share and the company completed a EUR 1 billion buyback, repurchasing 24.8 million shares (8.5% of share capital) in under one year.
The AGM also granted a new five‑year authorization for further share repurchases and highlighted FDA approval and the 2026 U.S. launch of the 5008X CAREsystem, supporting the FME Reignite strategy through 2030.